KODIAK SCIENCES INC. Operating Cash Flow
KODIAK SCIENCES INC. (KOD) reported Operating Cash Flow of -$86.25 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-13
- KODIAK SCIENCES INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$46.24M.
- KODIAK SCIENCES INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$40.01M.
- KODIAK SCIENCES INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$39.38M.
- KODIAK SCIENCES INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$32.88M.
- KODIAK SCIENCES INC. net cash provided by (used in) operating activities for fiscal 2025 was -$136.01M.
- KODIAK SCIENCES INC. net cash provided by (used in) operating activities for fiscal 2024 was -$117.32M.
- KODIAK SCIENCES INC. net cash provided by (used in) operating activities for fiscal 2023 was -$154.18M.
- KODIAK SCIENCES INC. net cash provided by (used in) operating activities for fiscal 2022 was -$206.46M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$46.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$86.25M 10-Q · filed 2026-08-13 | -$125.63M derived: sum of 3 quarters · filed 2026-08-13 | -$158.50M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$40.01M 10-Q · filed 2026-05-07 | -$79.39M derived: sum of 2 quarters · filed 2026-05-07 | -$112.27M derived: sum of 3 quarters · filed 2026-05-07 | -$146.94M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$39.38M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$72.26M derived: sum of 2 quarters · filed 2026-03-31 | -$106.93M derived: sum of 3 quarters · filed 2026-08-13 | -$136.01M 10-K · filed 2026-03-31 |
| 2025-09-30 | -$32.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$67.55M derived: sum of 2 quarters · filed 2026-08-13 | -$96.63M 10-Q · filed 2025-11-13 | -$126.70M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$34.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$63.75M 10-Q · filed 2026-08-13 | -$93.82M derived: sum of 3 quarters · filed 2026-08-13 | -$114.98M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$29.08M 10-Q · filed 2026-05-07 | -$59.15M derived: sum of 2 quarters · filed 2026-05-07 | -$80.30M derived: sum of 3 quarters · filed 2026-05-07 | -$106.80M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$30.07M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$51.23M derived: sum of 2 quarters · filed 2026-03-31 | -$77.72M derived: sum of 3 quarters · filed 2026-03-31 | -$117.32M 10-K · filed 2026-03-31 |
| 2024-09-30 | -$21.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$47.65M derived: sum of 2 quarters · filed 2025-11-13 | -$87.25M 10-Q · filed 2025-11-13 | -$119.49M derived: sum of 4 quarters · filed 2026-03-31 |
| 2024-06-30 | -$26.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$66.09M 10-Q · filed 2025-08-13 | -$98.33M derived: sum of 3 quarters · filed 2026-03-31 | -$131.10M derived: sum of 4 quarters · filed 2026-03-31 |
| 2024-03-31 | -$39.60M 10-Q · filed 2025-05-14 | -$71.84M derived: sum of 2 quarters · filed 2026-03-31 | -$104.60M derived: sum of 3 quarters · filed 2026-03-31 | -$146.56M derived: sum of 4 quarters · filed 2026-03-31 |
| 2023-12-31 | -$32.24M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$65.00M derived: sum of 2 quarters · filed 2026-03-31 | -$106.96M derived: sum of 3 quarters · filed 2026-03-31 | -$154.18M 10-K · filed 2026-03-31 |
| 2023-09-30 | -$32.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$74.72M derived: sum of 2 quarters · filed 2024-11-14 | -$121.94M 10-Q · filed 2024-11-14 | -$177.02M derived: sum of 4 quarters · filed 2025-03-27 |
| 2023-06-30 | -$41.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$89.18M 10-Q · filed 2024-08-14 | -$144.25M derived: sum of 3 quarters · filed 2025-03-27 | -$197.34M derived: sum of 4 quarters · filed 2025-03-27 |
| 2023-03-31 | -$47.22M 10-Q · filed 2024-05-15 | -$102.30M derived: sum of 2 quarters · filed 2025-03-27 | -$155.38M derived: sum of 3 quarters · filed 2025-03-27 | -$210.52M derived: sum of 4 quarters · filed 2025-03-27 |
| 2022-12-31 | -$55.08M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | -$108.16M derived: sum of 2 quarters · filed 2025-03-27 | -$163.30M derived: sum of 3 quarters · filed 2025-03-27 | -$206.46M 10-K · filed 2025-03-27 |
| 2022-09-30 | -$53.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$108.22M derived: sum of 2 quarters · filed 2023-11-14 | -$151.38M 10-Q · filed 2023-11-14 | -$210.42M derived: sum of 4 quarters · filed 2024-03-28 |
| 2022-06-30 | -$55.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$98.30M 10-Q · filed 2023-08-14 | -$157.33M derived: sum of 3 quarters · filed 2024-03-28 | -$209.28M derived: sum of 4 quarters · filed 2024-03-28 |
| 2022-03-31 | -$43.16M 10-Q · filed 2023-05-15 | -$102.19M derived: sum of 2 quarters · filed 2024-03-28 | -$154.14M derived: sum of 3 quarters · filed 2024-03-28 | -$190.81M derived: sum of 4 quarters · filed 2024-03-28 |
| 2021-12-31 | -$59.03M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | -$110.98M derived: sum of 2 quarters · filed 2024-03-28 | -$147.65M derived: sum of 3 quarters · filed 2024-03-28 | -$182.27M 10-K · filed 2024-03-28 |
| 2021-09-30 | -$51.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | -$88.61M derived: sum of 2 quarters · filed 2022-11-09 | -$123.23M 10-Q · filed 2022-11-09 | -$150.25M derived: sum of 4 quarters · filed 2023-03-28 |
| 2021-06-30 | -$36.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$71.29M 10-Q · filed 2022-08-09 | -$98.31M derived: sum of 3 quarters · filed 2023-03-28 | -$122.88M derived: sum of 4 quarters · filed 2023-03-28 |
| 2021-03-31 | -$34.63M 10-Q · filed 2022-05-10 | -$61.64M derived: sum of 2 quarters · filed 2023-03-28 | -$86.22M derived: sum of 3 quarters · filed 2023-03-28 | -$100.12M derived: sum of 4 quarters · filed 2023-03-28 |
| 2020-12-31 | -$27.02M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | -$51.59M derived: sum of 2 quarters · filed 2023-03-28 | -$65.50M derived: sum of 3 quarters · filed 2023-03-28 | -$83.43M 10-K · filed 2023-03-28 |
| 2020-09-30 | -$24.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | -$38.48M derived: sum of 2 quarters · filed 2021-11-09 | -$56.41M 10-Q · filed 2021-11-09 | -$67.70M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | -$13.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | -$31.84M 10-Q · filed 2021-08-09 | -$43.13M derived: sum of 3 quarters · filed 2022-03-01 | -$50.83M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | -$17.93M 10-Q · filed 2021-05-10 | -$29.23M derived: sum of 2 quarters · filed 2022-03-01 | -$36.92M derived: sum of 3 quarters · filed 2022-03-01 | -$49.87M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | -$11.29M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | -$18.99M derived: sum of 2 quarters · filed 2022-03-01 | -$31.94M derived: sum of 3 quarters · filed 2022-03-01 | -$39.15M 10-K · filed 2022-03-01 |
| 2019-09-30 | -$7.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | -$20.65M derived: sum of 2 quarters · filed 2020-11-09 | -$27.85M 10-Q · filed 2020-11-09 | -$36.19M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | -$12.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | -$20.16M 10-Q · filed 2020-08-10 | -$28.50M derived: sum of 3 quarters · filed 2021-03-01 | -$33.48M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | -$7.21M 10-Q · filed 2020-05-11 | -$15.55M derived: sum of 2 quarters · filed 2021-03-01 | -$20.53M derived: sum of 3 quarters · filed 2021-03-01 | -$24.98M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | -$8.34M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | -$13.32M derived: sum of 2 quarters · filed 2021-03-01 | -$17.77M derived: sum of 3 quarters · filed 2021-03-01 | -$29.03M 10-K · filed 2021-03-01 |
| 2018-09-30 | -$4.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | -$9.43M derived: sum of 2 quarters · filed 2019-11-12 | -$20.69M 10-Q · filed 2019-11-12 | -$25.59M derived: sum of 4 quarters · filed 2020-03-16 |
| 2018-06-30 | -$4.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | -$15.71M 10-Q · filed 2019-08-14 | -$20.60M derived: sum of 3 quarters · filed 2020-03-16 | |
| 2018-03-31 | -$11.26M 10-Q · filed 2019-05-15 | -$16.16M derived: sum of 2 quarters · filed 2020-03-16 | ||
| 2017-12-31 | -$4.90M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | -$17.66M 10-K · filed 2020-03-16 | ||
| 2017-09-30 | -$12.76M 10-Q · filed 2018-11-16 | |||
| 2016-12-31 | -$16.05M 10-K · filed 2019-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |